Brilliant Violet 785™ anti-mouse CD279 (PD-1
- 产品名称：
- Brilliant Violet 785™ anti-mouse CD279 (PD-1
- 产品类别：
- 抗体
- 产品编号：
- 135225
- 产品应用：
- 135225
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- PD-1 cDNA followed by PD-1-Ig fusion protein
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785? under optimal conditions.
- Concentration
- 0.2 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 785? excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
- Application References
(PubMed link indicates BioLegend citation) -
- Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
- Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
- Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
- Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
- Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
- Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
- Product Citations
-
- Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
- Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
- Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
- Weulersse M, et al. 2020. Immunity. 53(4):824-839.e10. PubMed
- Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
- Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
- B?ttcher JP, et al. 2018. Cell. 172:1022. PubMed
- Ambler R, et al. 2020. Science Signaling. 13(649):. PubMed
- Yang Y, et al. 2021. Nat Commun. 12:525. PubMed
- Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
- Rivadeneira DB, et al. 2020. Immunity. 51(3):548-560. PubMed
- Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed
- Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
- Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
- Goc J, et al. 2021. Cell. :. PubMed
- Leruste A, et al. 2020. Cancer Cell. 36(6):597-612.e8.. PubMed
- Phadke MS, et al. 2021. Cancer Immunol Res. 9:554. PubMed
- RRID
- AB_2563680 (BioLegend Cat. No. 135225)
- Structure
- A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
- Distribution
-
Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
- Function
- Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
- Ligand/Receptor
- B7-H1 (PD-L1) and B7-DC (PD-L2)
- Cell Type
- B cells, T cells
- Biology Area
- Cancer Biomarkers, Immunology, Inhibitory Molecules
- Molecular Family
- CD Molecules, Immune Checkpoint Receptors
- Antigen References
-
1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313
- Gene ID
- 18566 View all products for this Gene ID
- UniProt
- View information about CD279 on UniProt.org
